Page last updated: 2024-10-15

ammeline

Description

ammeline: causes retinal degeneration [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135408770
CHEBI ID28646
SCHEMBL ID36982
MeSH IDM0040093

Synonyms (62)

Synonym
CHEBI:28646
4,6-diamino-1,3,5-triazin-2-ol
s-triazin-2-ol, 4,6-diamino-
1,3,5-triazin-2(1h)-one, 4,6-diamino-
s-triazin-2-ol,6-diamino-
nsc9778
2,3,5-triazin-6-one
nsc-9778
1,5-triazin-2(1h)-one, 4,6-diamino-
ammelin
2-hydroxy-4,6-diamino-1,3,5-triazine
ammeline
C08733
645-92-1
2,4-diamino-1,3,5-triazin-6-one
A0676
2,4-diamino-6-hydroxy-1,3,5-triazine
3,4,5,6-tetrahydro-4,6-diimino-1,3,5-triazin-2(1h)-one
cyanurodiamide
2,6-diamino-1h-1,3,5-triazin-4-one
2,6-bis(azanyl)-1h-1,3,5-triazin-4-one
A834820
AKOS006223976
ammeline (van)
ammelin (van)
unii-lc8g9556q0
einecs 211-455-1
4,6-diamino-1,3,5-triazin-2(1h)-one
ai3-50983
lc8g9556q0 ,
nsc 9778
FT-0622303
AKOS015894773
diaminohydroxytriazine
cyanurdiamide
atrazine-desethyl-desisopropyl-2-hydroxy
4,6-diamino-2-hydroxy-1,3,5-triazine
ammeline-13c3
6am ,
SCHEMBL36982
4,6-diamino-1,3,5-triazin-2(5h)-one
DTXSID3060950 ,
ammeline, (4,6-diamino-5-triazin-2-ol)
ammeline,
mfcd00023186
AKOS027383197
atrazine-desethyl-desisopropyl-2-hydroxy, pestanal(r), analytical standard
6-amino-5-azacytosine
4,6-diamino-5h-1,3,5-triazine-2-one
ammeline; desethylisopropylhyroxyatrazine
ammeline = 2,4-diamino-6-hydroxy-s-triazine
Q4747227
2,4-diamino-1,3,5-triazine-6-one
D88306
AS-56019
SB83877
azacitidine impurity 10 (metformin impurity pound(c)
CS-0164694
cid 5281298
4,6-diamino-1h-1,3,5-triazin-2-one
EN300-4282413
diamino-1,3,5-triazin-2-ol
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
monohydroxy-1,3,5-triazine
diamino-1,3,5-triazineAny member of the class of 1,3,5-triazines that consists of a 1,3,5-triazine skeleton substituted by two amino groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (24)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (4.17)18.7374
1990's1 (4.17)18.2507
2000's2 (8.33)29.6817
2010's19 (79.17)24.3611
2020's1 (4.17)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other24 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]